Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Neoplasms|Breast Neoplasm|Breast Cancer|Triple-Negative Breast Cancer
Interventions: DRUG: Trilaciclib|DRUG: Gemcitabine|DRUG: Carboplatin
Sponsor: G1 Therapeutics, Inc.